Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese

Tomidahama Hospital

Status: Unknown

Conditions: Osteoporosis

Study type: Observational

Funder types: Other

Identifiers

NCT02166437

IRB TH No 6-3

Details and patient eligibility

About

In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly divided following daily teriparatide in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.

Full description

Registry criteria: Patients treated in the investigators hospital using teriparatide. Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (< young adult mean 65%).

Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants

Enrollment: 500 estimated patients

Sex: All

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• severe osteoporotic patients

Exclusion criteria

• cancer, hypercalcemia, etc (i.e. patients who could not use bisphosphonate, denosmab, teriparatide)

Trial design

500 participants in 3 patient groups

Alendronate

Description:

Patients treated with alendronate

Minodronate

Description:

Patients treated with minodronate

Denosmab

Description:

Patients treated with denosmab